Patents by Inventor Robert L. Hoffman

Robert L. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARP1 INHIBITORS AND USES THEREOF
    Publication number: 20260098024
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: January 26, 2023
    Publication date: April 9, 2026
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • MK2 inhibitors and uses thereof
    Patent number: 12545662
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: February 10, 2026
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 12421241
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: May 2, 2024
    Date of Patent: September 23, 2025
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • PARP1 inhibitors and uses thereof
    Patent number: 12384780
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: July 18, 2024
    Date of Patent: August 12, 2025
    Assignee: XinThera, Inc.
    Inventors: Qing Dong, Robert L. Hoffman, Stephen W. Kaldor, Joseph Robert Pinchman, Lynnie Trzoss, Porino Jinjo Va
  • PARP1 INHIBITORS AND USES THEREOF
    Publication number: 20250171418
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: January 26, 2023
    Publication date: May 29, 2025
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • PARP1 INHIBITORS AND USES THEREOF
    Publication number: 20250129051
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: October 21, 2024
    Publication date: April 24, 2025
    Inventors: Robert L. Hoffman, Michael R. Mish, James G. Taylor
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20240400569
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: May 2, 2024
    Publication date: December 5, 2024
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • Pyridinone MK2 inhibitors and uses thereof
    Patent number: 12139462
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: November 12, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • PARP1 INHIBITORS AND USES THEREOF
    Publication number: 20240368162
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Inventors: Qing DONG, Robert L. HOFFMAN, Stephen W. KALDOR, Joseph Robert PINCHMAN, Lynnie TRZOSS, Porino Jinjo VA
  • ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF
    Publication number: 20240279214
    Abstract: Described herein are ?4?7 integrin inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of ?4?7 integrin-mediated conditions, such as inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).
    Type: Application
    Filed: December 21, 2023
    Publication date: August 22, 2024
    Inventors: Robert L. HOFFMAN, Joseph Robert PINCHMAN, Porino Jinjo VA, Qing DONG
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 12006322
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: September 20, 2023
    Date of Patent: June 11, 2024
    Assignee: Xin Thera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • CRYSTALLINE FORMS OF AN MK2 INHIBITOR
    Publication number: 20240182449
    Abstract: Described herein are crystalline forms of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-3?-fluoro-2?-(3-(2-hydroxypropan-2-yl)-1H-pyrazol-1-yl)-5?,6-dimethyl-2H-[1,4?-bipyridin]-2-one (compound 1), or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: October 4, 2023
    Publication date: June 6, 2024
    Inventors: Jing LIU, Jayachandra P. REDDY, Daniel John GANLEY, Robert L. HOFFMAN
  • CRYSTALLINE FORMS OF A PARP1 INHIBITOR
    Publication number: 20240174669
    Abstract: Described herein are crystalline forms of 5-(4-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methylipiperazin-1-yl)-N-methylpicolinamide (compound 1), or a pharmaceutically acceptable salt of solvate thereof.
    Type: Application
    Filed: October 5, 2023
    Publication date: May 30, 2024
    Inventors: Jayachandra P. REDDY, Daniel John GANLEY, Robert L. HOFFMAN
  • MK2 inhibitors and uses thereof
    Patent number: 11987574
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: May 21, 2024
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20240109904
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 4, 2024
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • PARP1 inhibitors and uses thereof
    Patent number: 11939329
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • PYRIDINONE MK2 INHIBITORS AND USES THEREOF
    Publication number: 20230382864
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 30, 2023
    Inventors: Robert L. HOFFMAN, Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20230373969
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR, Robert L. HOFFMAN
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20230348473
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 2, 2023
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
    Patent number: 11802128
    Abstract: Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: October 31, 2023
    Assignee: Xinthera, Inc.
    Inventors: Robert L. Hoffman, Qing Dong, Stephen W. Kaldor, Lynnie Trzoss, Porino Jinjo Va